Tullis — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection.
BiotechHealthtechCambridge, US
Bernat Olle(Executive Officer, Director)Daniel Couto(Executive Officer)Mark Mullikin(Executive Officer)Jeffrey Silber(Executive Officer)Christopher Viehbacher(Director)
BoardJohn LaMattina(Director)
Board seatCurt LaBelle· per SEC Form D · $118.5M raise · filed Aug 2024
Co-investorsAMR Action FundK2 HealthVenturesSalica InvestmentsBNP ParibasBNP Paribas Asset Management Europe
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.